COST-EFFECTIVENESS OF TALQUETAMAB-TGVS VS IDECABTAGENE VICLEUCEL FOR TRIPLE-CLASS EXPOSED RELAPSED OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Rong, R. [1 ]
Tang, T. [1 ]
Shi, L. [1 ]
机构：
[1] Tulane Univ, New Orleans, LA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
P43
引用
收藏
页码：S10 / S10
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France
    Zhang, Wenjie
    Karampampa, Korinna
    Venkatachalam, Meena
    Cotte, Francois-Emery
    Dhanda, Devender
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 243 - 253
  • [2] Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma
    Mancuso, Katia
    Barbato, Simona
    Talarico, Marco
    Tacchetti, Paola
    Zamagni, Elena
    Cavo, Michele
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2025, 25 (01) : 27 - 46
  • [3] Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Madduri, Deepu
    Berdeja, Jesus
    Lonial, Sagar
    Raje, Noopur
    Lin, Yi
    Siegel, David
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Cavo, Michele
    Einsele, Hermann
    Goldschmidt, Hartmut
    Weisel, Katja
    Rambaldi, Alessandro
    Reece, Donna
    Petrocca, Fabio
    Massaro, Monica
    Connarn, Jamie N.
    Kaiser, Shari
    Patel, Payal
    Huang, Liping
    Campbell, Timothy B.
    Hege, Kristen
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (08): : 705 - 716
  • [4] Indirect Comparison of Linvoseltamab Versus Talquetamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
    Richter, Joshua
    Jagannath, Sundar
    Lee, Hans
    Hoffman, James E.
    Zonder, Jeffrey
    Zhou, Zheng-Yi
    Garcia-Horton, Viviana
    Fillbrunn, Mirko
    Wang, Hongjue
    Mattera, Matthew
    Ma, Wenxin
    Ma, Qiufei
    Inocencio, Timothy
    Xu, Yingxin
    Bergrath, Evelien
    Harnett, James
    Roccia, Tito
    Kroog, Glenn S.
    Lorenc, Karen Rodriguez
    Houvras, Yariv
    Bumma, Naresh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S274 - S275
  • [5] Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma
    Shah, Nina
    Mojebi, Ali
    Ayers, Dieter
    Cope, Shannon
    Dhanasiri, Sujith
    Davies, Faith E.
    Hari, Parameswaran
    Patel, Payal
    Hege, Kristen
    Dhanda, Devender
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (10) : 737 - 749
  • [6] CHARACTERIZING CELLULAR KINETICS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS- EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
    Wu, F.
    Zheng, X.
    Burnett, J.
    Zhou, J.
    Chen, Y.
    Caia, A.
    Cook, M.
    Kondic, A.
    Lamba, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S52 - S52
  • [7] Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Ye, Jing Christine
    Biran, Noa
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Ammann, Eric
    Renaud, Thomas
    Kane, Colleen
    Parekh, Trilok
    Gray, Kathleen
    Zhang, Xinke
    Costa, Luciano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S99 - S100
  • [8] CHARACTERIZING EXPOSURE-RESPONSE RELATIONSHIPS OF IDECABTAGENE VICLEUCEL IN PATIENTS WITH TRIPLE-CLASS-EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zhou, J.
    Burnett, J.
    Zheng, X.
    Chen, Y.
    Caia, A.
    Cook, M.
    Kondic, A.
    Lamba, M.
    Wu, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S82 - S82
  • [9] Single-center experience with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma
    Sanoyan, D. Akhoundova
    Bacher, U.
    Kronig, M. -N.
    Seipel, K.
    Daskalakis, M.
    Pabst, T.
    SWISS MEDICAL WEEKLY, 2022, 152 : 64S - 64S
  • [10] Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Ye, Jing Christine
    Biran, Noa
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Ammann, Eric
    Renaud, Thomas
    Kane, Colleen
    Parekh, Trilok
    Gray, Kathleen
    Peterson, Steve
    Costa, Luciano J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2025, 25 (02):
12345